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1. Introduction
  Obesity, which results from a prolonged energy imbalance 
during intake exceeds expenditure, constitutes one of the 
most widespread metabolic disorders in contemporary 
society. It is closely related to hypertension, type 2 diabetes, 
coronary heart disease, cancer, respiratory complications 
and osteoarthritis[1,2]. The regulation of energy homeostasis 
for metabolic diseases is one of the most rapidly advancing 
subjects in biomedical research today. Breakthroughs in 
understanding of the molecular mechanisms regulating 
body weight have also provided potential opportunities for 
therapeutic intervention and brought renewed hope and 
vitality for the development of antiobesity drugs[3-6].
  The potential of natural products for the treatment of 
obesity is still largely unexplored and might be an excellent 
alternative strategy for the development of safe and effective 
antiobesity drugs. It has shown that some phytochemicals in 
traditional medicinal plants present an exciting opportunity 
for the development of newer treatment of obesity and other 
metabolic diseases.
  Lagenaria siceraria fruit (Cucurbitaceae), popularly 
known as Bottle gourd, is a common vegetable for Indians. 
Lagenaria siceraria is a pubescent or trailing herb with 
bottle-shaped fruits. In India, Lagenaria siceraria fruits 
are frequently used to treat a large variety of ailments and 
symptoms of hyperlipidemia and atherosclerotic impasse. 
Lagenaria siceraria fruits are traditionally used for its 
cardioprotective, cardiotonic and diuretic properties[7]. It 
also cures pain, ulcers, jaundice and fever, and used to treat 
pectoral cough, asthma and other bronchial disorders[8-12].
Some studies have reported that Lagenaria siceraria 
fruit is effective on decreasing the levels of total lipids[7]. 
Lagenaria siceraria fruit also shows antioxidant activity[13]. 
Lagenin-a novel protein is isolated and characterized from 
Lagenaria siceraria fruits for its anticancer activity[14]. 
Early work showed that semipurified dietary fibers isolated 
from Lagenaria siceraria fruits affects fecal excretion of 
steroids[15].
  It is well-established that diet rich in vegetables and 
fruits can reduce cardiovascular diseases[16,17]. However, it 
has not yet been reported whether Lagenaria siceraria fruit 
affects on fat amassment and serum tumor necrosis factor-
毩 (TNF-毩) in high fat diet (HFD) induced obese rats. 
Objective: To investigate the effects of ethanolic extract of Lagenaria siceraria fruit (ELSF) on  fat 
amassment and serum TNF-毩 in high-fat diet-induced obese rats. Methods: The high fat diet 
induced obese rats were orally treated with orlistat (50 mg/kg) and ELSF (100, 200, 300 mg/kg/day)
to the respective treatment groups. The body weight, fasting blood glucose level, lipid profile, 
serum levels of tumor necrosis factor-毩 (TNF-毩) in rats were measured after 30 days of 
treatment and compared to the obese control animals. Results: ELSF significantly (P < 0.001) 
reduced the body weight gain, fasting blood glucose, total cholesterol, triglyceride, total protein 
and TNF-毩. Conclusions: These encouraging findings suggest that Lagenaria siceraria has 
excellent pharmacological potential to prevent fat amassment.
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Therefore, an attempt has been made to investigate the effect 
of ethanolic extract of Lagenaria siceraria fruit (ELSF) on the 
fat amassment and serum TNF-毩 in high-fat diet-induced 
obese rats.
2. Materials and methods
2.1. Collection and authentication of plant
  The fresh fruits of Lagenaria siceraria were collected 
in the month of March 2010 from the Wardha District 
of Maharashtra, India. The fruits were authenticated 
by Dr.Thakare, Rashtrasant Tukadoji Maharaj Nagpur 
University, Nagpur and voucher specimen LP-09011is 
lodged in our research laboratory for the future reference.
2.2. Animals
  Albino Wistar rats of either sex weighing between 150 and 
180 g were used for the present study. The animals were 
maintained under standard environmental conditions and 
were fed with standard pellet diet and water ad libitum. 
The study was approved by Institutional Animal Ethics 
Committee (Reg. no.784/03/C/CPCSEA/5). The guidelines 
of CPCSEA, India, were strictly followed during the 
maintenance and experiment.
2.3. Chemicals
  Biochemical kits for the estimation of glucose (GOD-POD), 
total triglycerides (GPO-POD), total cholesterol (CHOD-POD), 
high density lipoprotein (PEG), and total protein (Biuret) 
were purchased from Crest Biosystems Kits (India). Serums 
TNF-毩 level in rats were measured by use of commercially 
available rat enzyme-linked immunosorbent assay kit. 
Normal diet (ND) and HFD were obtained from ACP, Wardha. 
2.4. Preparation of crude extract
  The fresh fruits of Lagenaria siceraria were sliced, shade 
dried, coarsely powdered and cold macerated with ethanol to 
obtain ethanolic extract. The solvent extract was evaporated 
in vacuo (40 曟). The yield recorded was 24.7% (w/w). The 
extract (1%, w/v) was dissolved in distilled water for oral 
administration to experimental animals.
2.5. Phytochemical screening of ELSF 
  ELSF was subjected to phytochemical screening[18] for the 
detection of various phyto-constituents.
2.6. Toxicity studies 
  Toxicity studies were carried out on normal healthy rats. 
The ELSF (50, 100, 150, 200, 300 mg/kg/day) was administered 
orally for 4 days of six groups of rats (n=6) and the animals 
were kept under observation for mortality as well as any 
behavioral changes.
2.7. Experimental models
2.7.1. Induction of obesity 
  After 7 days of acclimatization , animals were randomly 
divided into 6 groups (n=6): normal control group, HFD 
control group and remaining 栿-桍 as treatment groups. 
Animals in normal control group were fed with ND while the 
other groups were fed with HFD[19,20] ad libitum, throughout 
the experiment.
2.7.2. Experimental design and treatment protocol 
  The animals were divided into six groups of six animals 
each as follows:
Group栺: Non-obese control (NOB) rats fed with ND 
throughout the course of study;
Group 栻: Obese control (OB) rats fed with HFD for 30 days;
Group 栿: Obese rats given orlistat suspension prepared with 
saline 50 mg/kg, p.o. for 30 days;
Groups 桇: Obese rats given ELSF100 mg/kg, p.o. for 30 days;
Groups桋: Obese rats given ELSF 200 mg/kg, p.o. for 30 days;
Groups 桍: Obese rats given ELSF 300 mg/kg, p.o. for 30 
days.
2.7.3. Determination of body weight
  During the experimental period, change in body weight of 
each rat was measured once in a week of ELSF treatment.
2.7.4. Estimation of plasma glucose, serum levels of TNF-毩 
and lipid profile 
  Plasma glucose, serum levels of TNF-毩 and lipid profiles 
of all the rats were determined on 30 day (post-treatment). 
The blood samples were collected from each rat by retro-
orbital venepucture of the overnight fasted rats into micro 
centrifuge tubes containing heparin (10 毺L, 1 000 IU/mL). 
Biochemical parameters were estimated using commercially 
available diagnostic kits. 
2.8. Statistical analysis
  Statistical analysis was carried out by using Graph-Pad 
Instat statistical package (Graphpad Software Inc.). Values 
are expressed as mean依SEM. For multiple comparisons, one 
way ANOVA was used followed by Tukey test P value less 
than 0.05 was regarded to be significant. 
3. Results
3.1. Phytochemical screening of ELSF
  Phytochemical screening revealed that ELSF showed the 
presence of flavonoids, saponins, steroids and polyphenolic 
compounds. 
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3.2. Effect of ElSF on body weight 
  One-way ANOVA followed by Tukey’s test revealed that 
body weight was slightly increased in non-obese control rats 
compared to initial body weight whereas HFD induced obese 
rats shows marked increase of body weight [(268.50依1.57) g] 
after 30 days as compared with initially weight of obese rats 
[(258.40依1.56) g]. The weight gain effect evidenced in orlistat 
(50 mg/kg; p.o.) treated rats was [(187.00依1.67) g] and treatment 
with ELSF (300 mg/kg; p.o.) groups showed most significant
(P < 0.001) reduction in weight gain [(189.80依1.62) g] as 
compared to OB group (Table 1).
Table 1
Effect of ELSF on body weight (g) in normal and obese rats (mean依
SEM, n = 6).
Group Initial body weight Final body weight 
Non-obese control 162.60依1.22 167.80依1.42
Obese control 258.40依1.56 268.50依1.57#
Orlistat (50 mg/kg; p.o.) 195.50依1.40 185.00依1.67***
ELSF (100 mg/kg; p.o.) 209.70依1.06 198.80依1.60**
ELSF (200 mg/kg; p.o.) 200.20依1.38 192.70依1.63***
ELSF (300 mg/kg; p.o.) 198.80依1.63 189.80依1.62***
Values are statistically significant at # P < 0.001 vs. nonobese 
group; ***P < 0.001, **P < 0.01, *P < 0.05 vs. obese control group 
respectively (One-way ANOVA followed by Tukey’s post hoc test).
3.3. Effect of ELSF on fasting blood glucose
  One-way ANOVA indicated the significant influence of 
ELSF on elevation of fasting blood glucose. On 30 days of 
treatment with ELSF 300 mg/kg; p.o. [(92.67依3.58) mg/dL] 
as compared to OB group [(157.70依3.21) mg/dL] exhibited 
significant (P<0.001). Orlistat (50 mg/kg, p.o.) also showed 
significant (P<0.001) reduction of fasting blood glucose levels 
[(90.33依3.92) mg/dL] as compared to OB group (Table 2).
3.4. Effect of ELSF on serum TNF-毩 level
  One-way ANOVA indicated the significant influence serum 
TNF-毩 level were increased in obese control rats fed with 
HFD compared with NOB group (Table 2) [Group I, (2.60依0.62) 
pg/mL; group II, (4.37依1.14) pg/mL; P < 0.001]. In contrast, 
TNF-毩 level were decreased in ELSF (300 mg/kg; p.o) 
treated groups compared with OB group [(2.05依1.16) pg/mL; P 
< 0.001]. On the other hand, orlistat (50 mg/kg, p.o.) showed 
significant [(1.95依1.37) pg/mL; P < 0.001] effect in serum 
TNF-毩 level as compared to the OB (Table 2).
3.5. Effect of ELSF on lipid profile 
  HFD treatment resulted in  total cholesterol (TC), 
triglycerides (TG),  low density lipoprotein (LDL), very low 
density lipoprotein (VLDL), total protein (TP) and reduction 
in high density-lipoprotein level (HDL) as compared to the 
NOB rats as noted at end of the study (Table 2). When OB 
rats treated with ELSF (300 mg/kg; p.o.) for 30 days showed 
most significant (P < 0.001) reduction in TC level [(101.90
依3.89) mg/dL], TG level [(197.30依7.70) mg/dL], LDL level 
[(47.90依1.01) mg/dL], VLDL level [(39.40依1.54) mg/dL], TP 
level [(6.14依0.30) g/dL]. Conversely, HDL cholesterol level 
were significantly (P < 0.001) increased [(45.80依4.38) mg/dL] 
in the ELSF treated groups at the 30 days of treatment as 
compared to OB group. However, the standard drug orlistat 
(50 mg/kg,  p.o.) markedly exerted the most significant
(P < 0.001) effects as: TC level [(99.40依1.82) mg/dL], TG level 
[(193.30依3.01) mg/dL], LDL level [(46.40依2.71 mg/dL], VLDL 
level [(37.00依 0.60) mg/dL], TP level [(5.68依0.17) g/dL] and 
HDL level [(47.90依2.32) mg/dL]  on 30 days as compared to 
the OB (Table 2). 
Table 2
Effect of ELSF on plasma glucose rate, serum TNF-毩 level and lipid profile in normal and obese rats (mean依SEM, n = 6). 
Biochemical parameters Days Group 栺 Group 栻 Group 栿 Group 桇 Group 桋 Group 桍
Fasting blood sugar (mg/dL)   0   86.23依5.16 112.33依4.03   98.35依5.84 110.00依6.24   98.23依4.08   99.50依5.76
30   84.00依6.03 157.70依3.21#   90.33依3.92***   99.00依10.37*   94.50依4.03***   92.67依3.58***
TC(mg/dL)   0   71.30依1.60 119.00依1.30 140.10依1.67 149.30依0.81 154.10依0.87 131.30依0.60
30   78.60依2.05 158.30依2.90#   99.40依1.82*** 134.30依4.46* 123.00依6.21** 101.90依3.89 ***
TG(mg/dL)   0 164.40依0.54 212.50依0.49 224.50依0.80 223.40依0.75 221.30依0.55 228.60依1.47
30 172.60依1.69 244.90依2.65# 193.30依3.01*** 219.20依0.85* 218.30依2.70* 197.30依7.70 ***
HDL(mg/dL)   0   32.50依0.80   35.00依0.61   39.03依1.02   36.00依0.77   35.40依0.75   34.70依0.89
30   35.70依0.54   32.80依0.72 ns   47.90依2.32***   42.00依1.01*   43.90依2.13*   45.80依4.38**
LDL(mg/dL)   0   15.70依0.83   63.50依0.92   60.30依0.89   67.70依1.04   62.70依1.07   61.90依0.97
30   17.80依3.60   69.50依1.76#   46.40依2.71***   53.40依5.16*   49.60依5.06**   47.90依1.01***
VLDL(mg/dL)   0   31.30依0.71   41.70依0.66   51.40依0.76   54.70依0.71   57.70依0.65   54.50依0.79
30   34.50依0.33   48.90依0.53#   37.00依0.60***   44.40依0.54*   44.80依0.17*   39.40依1.54***
TP(g/dL)   0     3.69依0.18     8.45依0.34     8.67依0.12     8.88依0.23     8.98依0.49     8.20依0.27
30     5.29依0.13   10.42依0.24#     5.68依0.17***     8.48依0.22*     8.16依0.56 **     6.14依0.30 ***
TNF-毩( pg/mL)   0     2.98依1.55     2.92依2.10     2.89依3.11     3.18依0.56     3.29依3.36     2.97依3.67
30     2.60依0.62     4.37依1.14#     1.95依1.37***     2.78依1.47*     2.68依2.22*     2.05依1.16***
Group-栺 served as non-obese control. Group-栻 served as obese control. Group 栿 received 50 mg/kg (p.o.) of orlistat (positive control). Group 
桇 received 100 mg/kg (p.o.) of ELSF. Group 桋 received 200 mg/kg (p.o.) of ELSF. Group 桍 received 300 mg/kg (p.o.) of ELSF. Values are 
statistically significant at # P < 0.001 vs. non-obese group; ns-nonsignificant (P > 0.05) vs. non-obese group;***P < 0.001, **P < 0.01, *P < 
0.05 vs. obese control group.
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4. Discussion 
  There is overwhelming evidence that obese individuals 
have a substantially higher risk of developing many diseases 
such as type 2 diabetes, hyperlipidemia, cardiovascular 
disease and hypertension[21,22]. Thus the quest for possible 
compounds to aid in the treatment of obesity has intensified. 
 In the present study albino wistar rats, a widely known 
model for studying obesity and related metabolic disorders 
were used. The results indicated that the ELSF (100-300 
mg/kg/day; p.o.) when administered for 30 days showed 
beneficial effects in fat amassment. 
  Several studies divulge that a significant reduction in 
fasting blood glucose level of obese rats. Treatment with 
ELSF (100, 200 and 300 mg/kg, p.o.) for 30 days significantly 
reduced TC, TG, TP, LDL and VLDL associated with 
significant increased in HDL level in obese rats. Orlistat (50 
mg/kg; p.o.) has also been included in the study in order 
to understand how far activity of ELSF is comparable to 
that of a standard drug. Since HDL is responsible for the 
transportation of cholesterol from peripheral tissues to 
the liver for metabolism[23]. The weight loss in obese rats 
may be associated with lipid lowering activity of ELSF or 
due to its influence on various lipid regulation system. 
Hence, treatment with ELSF (100, 200 and 300 mg/kg body 
weight) in rats have potential role to prevent formation 
of atherosclerosis disease[24]. ELSF significantly reduced 
both the TC and LDL cholesterol. Recent studies also 
shows that triglycerides are directly or indirectly related 
to coronary heart diseases[25]. TNF-毩, a cytokine secreted 
by adipocytes, influences energy balance and glucose 
homeostasis. TNF-毩 causes insulin resistance and plays a 
major role in the pathogenesis of obesity-linked DM II [26,27]. 
Serum TNF-毩 level increased in obesity and may be the 
strong correlation between total cholesterol and serum TNF-毩
level[28,29]. We also found increased serum TNF-毩
level in animals receiving a high-fat diet. In the absence of 
a high-fat diet, serum TNF-毩 level was lower to the NOB 
group. Serum TNF-毩 level was significant reduced in ELSF 
treated groups compared with obese control group. 
  The mechanisms by which ELSF causes a reduction in 
body weight gain are not yet clear. However, potential 
mechanisms include reductions in plasma cholesterol levels 
and triglyceride, inhibition of lipid droplet accumulation in 
fat and biochemical characteristics. 
  Phytochemical screening revealed that the presence of 
flavonoids, saponins, steroids and polyphenolic compounds 
in the ELSF. Supplementation of ELSF itself contributed to 
the reduced body weight gain when compared to the OB 
group, which suggests that other functional factor(s) could be 
present in the ELSF, for instance, polyphenolic compounds 
and flavonoids. Generally, a high-fat diet significantly 
increases the total cholesterol level in serum and triglyceride 
level in rats. Supplementation of ELSF significantly lowered 
total cholesterol and triglyceride level, by compared to 
the OB group. This could be related to the high contents of 
saponins, steroids and flavonoids in ELSF. Several studies 
show that plant saponins and steroids are known to possess 
both hypolipidemic and antihyperlipidemic activities[7]. 
Flavonoids and other polyphenolic compounds have also 
suggested for their hypocholesterolemic and hypolipidemic 
effects[30]. In conclusion, our study demonstrates that ELSF 
inhibit fat amassment in high-fat diet-induced obese rats 
and related metabolic disorders. 
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